JG
ALNY icon

Jefferies Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Jefferies Group’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$18.7M Buy
93,600
+61,500
+192% +$11.7M 0.16% 99
2022
Q2 		$4.68M Buy
32,100
+12,500
+64% +$1.77M 0.04% 373
2022
Q1 		$3.2M Sell
19,600
-34,600
-64% -$5.27M 0.02% 526
2021
Q4 		$9.19M Buy
54,200
+30,000
+124% +$5.58M 0.05% 294
2021
Q3 		$4.57M Buy
24,200
+4,200
+21% +$788K 0.03% 462
2021
Q2 		$3.39M Buy
+20,000
New +$2.93M 0.02% 577
2021
Q1 		– Sell
-30,300
Closed -$3.94M – 1591
2020
Q4 		$3.94M Sell
30,300
-30,000
-50% -$4.01M 0.03% 491
2020
Q3 		$8.78M Buy
60,300
+300
+0.5% +$42.6K 0.1% 171
2020
Q2 		$8.89K Hold
60,000
– – 0.1% 158
2020
Q1 		$6.53M Buy
+60,000
New +$6.93M 0.07% 237
2019
Q4 		– Sell
-15,000
Closed -$1.21M – 2533
2019
Q3 		$1.21M Buy
+15,000
New +$1.19M 0.01% 1406
2018
Q4 		– Sell
-9,800
Closed -$858K – 2130
2018
Q3 		$858K Buy
+9,800
New +$986K 0.01% 1406
2018
Q2 		– Sell
-45,600
Closed -$5.43M – 2284
2018
Q1 		$5.43M Buy
45,600
+600
+1% +$77.4K 0.03% 435
2017
Q4 		$5.72M Sell
45,000
-96,300
-68% -$12.1M 0.03% 513
2017
Q3 		$16.6M Buy
+141,300
New +$12.1M 0.11% 165
2016
Q2 		– Sell
-3,600
Closed -$226K – 2111
2016
Q1 		$226K Sell
3,600
-13,300
-79% -$884K ﹤0.01% 1799
2015
Q4 		$1.59M Hold
16,900
– – 0.01% 969
2015
Q3 		$1.36M Buy
16,900
+7,900
+88% +$878K 0.01% 1077
2015
Q2 		$1.08M Buy
+9,000
New +$1.08M 0.01% 1208
2014
Q2 		– Sell
-47,600
Closed -$3.2M – 2045
2014
Q1 		$3.2M Buy
+47,600
New +$3.69M 0.03% 451

Other funds holding ALNY

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Jefferies Group's ALNY Position: Q3 2022 in Review

Jefferies Group increased its Alnylam Pharmaceuticals (ALNY) stake by 177% in Q3 2022, buying an estimated $5.69M and bringing the position to 46,726 shares worth $9.35M. The position accounts for 0.08% of the portfolio, ranked #202.

Jefferies Group first reported a position in ALNY in Q2 2013 and has held it in 24 quarters since. 496 funds tracked by Wall St. Rank hold ALNY as of Q3 2022.

  • Jefferies Group held 46,726 shares of Alnylam Pharmaceuticals worth $9.35M as of Q3 2022.
  • Jefferies Group bought 29,831 Alnylam Pharmaceuticals shares in Q3 2022, an estimated $5.69M.
  • Alnylam Pharmaceuticals made up 0.08% of Jefferies Group's portfolio in Q3 2022, its #202 holding.
  • Jefferies Group first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 24 quarters since.
  • 496 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2022.

Based on Jefferies Group's 13F filing for Q3 2022, filed 14 Nov 2022.